A rush for immunotherapy cancer drugs means new bedfellows – The Economist
The Economist |
A rush for immunotherapy cancer drugs means new bedfellows
The Economist The drug, Imfinzi, and the experimental drug tremelimumab, belong to a new category of immunotherapy medicines called “checkpoint inhibitors”. Similar drugs are made by Bristol Myers Squibb (BMS), by Merck in America and Roche, a Swiss firm. AstraZeneca plc: Buy the Dip? |
